# Magnolia Neurosciences Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magnolia-neurosciences

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.magnolianeurosciences.com
- Total disclosed funding: $8M
- Latest round: Series A (Aug 3, 2018)
- Investors on record: 12

## About

Magnolia Neurosciences Corporation specializes in innovative software solutions that enhance operational efficiencies across various sectors, including finance, healthcare, and logistics, primarily serving small to medium-sized enterprises and larger corporations.Magnolia Neurosciences Corporation is focused on delivering advanced software solutions designed to streamline business operations. The company is headquartered in New York, US. On November 23, 2021, the company raised USD 13.000 mn in Series A funding, which brings its total amount raised to USD 13.000 mn, valuing the company at USD 38.633 mn post-money. The founder's history and previous ventures remain unspecified.The company offers a range of innovative products and services designed to address specific needs within its target market. Its core offerings include advanced software solutions that streamline operational efficiencies for businesses in various sectors, including finance, healthcare, and logistics. These products are engineered to enhance productivity, reduce costs, and improve overall user experience, catering primarily to small and medium-sized enterprises (SMEs) and larger corporations. The solutions have been deployed in multiple geographical markets, including North America, Europe, and parts of Asia, where they have been met with positive reception from both end-users and businesses looking to optimize their processes. The company’s approach emphasizes user-friendly interfaces and robust customer support, ensuring that clients can effectively implement and maximize the utility of the products.The company generates revenue through a structured model that primarily includes subscription-based services and direct sales of its software solutions. Clients typically engage in annual or monthly subscription plans, which provide access to the full suite of features and continuous updates. This model fosters a stable recurring revenue stream, allowing the company to maintain strong relationships with its customer base. Additionally, the company engages in B2B transactions, collaborating with larger enterprises to provide tailored solutions that meet specific operational requirements. Flagship products form the backbone of its offerings, contributing significantly to revenue through their adoption in various industries, which underscores the company’s strategic focus on delivering high-quality, reliable software solutions to its clients.Magnolia Neurosciences Corporation plans to utilize its recent Series A funding of USD 13.000 mn raised in November 2021 to support the development of upcoming products aimed at expanding its market presence. The company is targeting further expansion into geographical markets, specifically aiming to penetrate additional regions in Europe and Asia by the end of 2023. This funding will enable the company to enhance product development and market outreach, facilitating its growth strategy.

## Funding rounds

- Series A, Aug 3, 2018, $8M — ARCH Venture Partners, Alexandria Venture Investments, Johnson & Johnson Innovation, 180 Degree Capital, Pfizer Venture Investments, AbbVie Ventures, Accelerator Life Science Partners, Eli Lilly & Company, Partnership Fund for New York City, SCP Buffalo Incubator Innovate NY Fund LP, Watson Fund, Wuxi AppTec Group

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- Eli Lilly & Company — Series A
- Partnership Fund for New York City (https://capitalatlas.ai/funds/partnership-fund-for-new-york-city) — Series A
- SCP Buffalo Incubator Innovate NY Fund LP — Series A
- Watson Fund (https://capitalatlas.ai/funds/watson-fund) — Series A
- Wuxi AppTec Group — Series A